• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Orphan Drug Designation and Exclusivity for "Same Drugs".

作者信息

Hong Phebe, Sarpatwari Ameet, Kesselheim Aaron S

机构信息

Phebe Hong is at the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, and a student at Harvard Law School. Ameet Sarpatwari, J.D., Ph.D., is at the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Aaron S. Kesselheim, M.D., J.D., M.P.H., leads the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

J Law Med Ethics. 2019 Jun;47(2):347-349. doi: 10.1177/1073110519857293.

DOI:10.1177/1073110519857293
PMID:31298092
Abstract
摘要

相似文献

1
Orphan Drug Designation and Exclusivity for "Same Drugs".罕见病药物认定及“同类药物”的排他权
J Law Med Ethics. 2019 Jun;47(2):347-349. doi: 10.1177/1073110519857293.
2
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.联邦针对指定为孤儿药的药品的340B计划支付方案：需要国会作出澄清以堵住政府与行业间的旋转门。
J Clin Oncol. 2016 Dec 20;34(36):4320-4322. doi: 10.1200/JCO.2016.68.2989. Epub 2016 Oct 31.
3
Regulators adopt more orphan drugs.监管机构批准了更多孤儿药。
Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a.
4
The Orphan Drug Act Revisited.《孤儿药法案》再探讨。
JAMA. 2019 Mar 5;321(9):833-834. doi: 10.1001/jama.2019.0290.
5
Four Decades of Orphan Drugs and Priorities for the Future.四十年的孤儿药及未来优先事项
N Engl J Med. 2024 Jul 11;391(2):100-102. doi: 10.1056/NEJMp2401487. Epub 2024 Jul 6.
6
1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.1992年勒图尔诺奖。美国药品监管问题。药物滞后与孤儿药。
J Leg Med. 1993 Dec;14(4):617-39. doi: 10.1080/01947649309510932.
7
Experimental use and the Orphan Drug Act: a biotechnology conundrum.实验性使用与《孤儿药法案》：一个生物技术难题。
Nat Biotechnol. 1996 Apr;14(4):511-2. doi: 10.1038/nbt0496-511.
8
Rare diseases, orphan drugs, and orphaned patients.罕见病、孤儿药与被忽视的患者。
Mol Interv. 2006 Aug;6(4):186-91. doi: 10.1124/mi.6.4.2.
9
Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.评估《孤儿药法案》七年市场独占期的影响。
Health Aff (Millwood). 2018 May;37(5):732-737. doi: 10.1377/hlthaff.2017.1179.
10
Abuses of FDA Regulatory Procedures - The Case of Suboxone.美国食品药品监督管理局监管程序的滥用——以舒倍生为例
N Engl J Med. 2020 Feb 6;382(6):496-498. doi: 10.1056/NEJMp1906680. Epub 2020 Jan 8.